Answers are grounded in this paper and cite their sources.
This position paper discusses the assumptions and clinical implications of the 2024 ESC guidelines regarding antianginal medical therapy for chronic coronary syndrome.
According to the 2024 ESC guidelines for the management of chronic coronary syndrome antianginal medical therapy aims to control symptoms while ensuring acceptable tolerability and patient adherence. The guidelines specify the indications for particular groups of antianginal drugs, defining the class of indications and the level of evidence based on the results of expert opinions, registries, clinical studies, and meta-analyses. This very important document has a great impact on clinical practice as it constitutes the basis for therapeutic decisions. Therefore, it is worth understanding the assumptions that guided the authors when formulating specific recommendations. As the investigators of the ELCTRA -SIRIO 2 trial*, we are monitoring new scientific evidence and new guidelines that may impact our study protocol.
No takes yet. Share an insight, caveat, or question.
Kubica et al. (2024) conducted a review in chronic coronary syndrome. antianginal medical therapy was evaluated. The 2024 ESC guidelines for chronic coronary syndrome provide updated recommendations on antianginal medical therapy, prompting investigators to monitor new evidence for ongoing trial protocols.
Synapse has enriched 10 related papers. Consider them for comparative context: